User login
Intradermal injection of botulinum toxin was an effective and safe method of treating facial erythema of rosacea, according to Dr. Bradley Bloom, of the Laser & Skin Surgery Center of New York, and his associates.
Of 15 patients, the mean baseline erythema grade was 1.8, and the mean erythema grade at 3 months after treatment was 1. The treatment resulted in statistically significant improvement in erythema at 1, 2, and 3 months after treatment when compared with baseline, according to the researchers. The patients were of Fitzpatrick skin Types I to III with a mean age of 54 years, and 80% were women
Because of the promising results, further and more extensive trials are recommended, but further investigation is needed to elucidate the mechanism of action by which botulinum toxin improves facial flushing of rosacea, the researchers said.
Read the full article at Dermatologic Surgery (doi: 10.1097/DSS.0000000000000277).
Intradermal injection of botulinum toxin was an effective and safe method of treating facial erythema of rosacea, according to Dr. Bradley Bloom, of the Laser & Skin Surgery Center of New York, and his associates.
Of 15 patients, the mean baseline erythema grade was 1.8, and the mean erythema grade at 3 months after treatment was 1. The treatment resulted in statistically significant improvement in erythema at 1, 2, and 3 months after treatment when compared with baseline, according to the researchers. The patients were of Fitzpatrick skin Types I to III with a mean age of 54 years, and 80% were women
Because of the promising results, further and more extensive trials are recommended, but further investigation is needed to elucidate the mechanism of action by which botulinum toxin improves facial flushing of rosacea, the researchers said.
Read the full article at Dermatologic Surgery (doi: 10.1097/DSS.0000000000000277).
Intradermal injection of botulinum toxin was an effective and safe method of treating facial erythema of rosacea, according to Dr. Bradley Bloom, of the Laser & Skin Surgery Center of New York, and his associates.
Of 15 patients, the mean baseline erythema grade was 1.8, and the mean erythema grade at 3 months after treatment was 1. The treatment resulted in statistically significant improvement in erythema at 1, 2, and 3 months after treatment when compared with baseline, according to the researchers. The patients were of Fitzpatrick skin Types I to III with a mean age of 54 years, and 80% were women
Because of the promising results, further and more extensive trials are recommended, but further investigation is needed to elucidate the mechanism of action by which botulinum toxin improves facial flushing of rosacea, the researchers said.
Read the full article at Dermatologic Surgery (doi: 10.1097/DSS.0000000000000277).